Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Bacteriophage Lysins in the Era of Antibiotic Resistance"
A special issue of Antibiotics (ISSN 2079-6382). This special issue belongs to the section "Novel Antimicrobial Agents".
Deadline for manuscript submissions: closed (30 November 2021) | Viewed by 16340
Special Issue Editor
Interests: bacteriophage; lysin; rapid microbial detection; African swine fever virus
Special Issue Information
The World Health Organization has listed microbial resistance to antibiotics among the major global health threats. It is not rare to see infections caused by bacteria resistant to all of the current antibiotics, leading to increased morbidity and mortality. This global challenge is provoking a high interest in seeking alternatives to traditional antibiotics. Bacteriophage lysins are hydrolytic enzymes capable of specifically recognizing the bacterial cell wall to cleave peptidoglycan for the release of progeny virions during the lytic cycle of bacteriophage. The advantages of lysins include fast bactericidal activity and low chance for bacteria to generate resistance. The number of studies on lysins has increased significantly in recent years. Some lysins are in the phase III clinical trial stage for treating antibiotic resistant infections. The aim of this Special Issue is to provide readers with an updated overview of the field, highlighting the most recent advances in lysin research, both in preclinical and clinical settings.
We welcome contributions including, but not limited to, the following topics:
- Discovery and engineering variants of lysins;
- Synergistic combinations with other antimicrobials;
- Safety and host immune response;
- Development of lysins into pharmaceutical products;
- Other applications of lysins, such as in agriculture and cosmetics.
Prof. Dr. Hongping Wei
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Antibiotic resistance